WallStreetZenWallStreetZen

NASDAQ: RARE
Ultragenyx Pharmaceutical Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RARE

Based on 11 analysts offering 12 month price targets for Ultragenyx Pharmaceutical Inc

Min Forecast
$45.00+82.19%
Avg Forecast
$65.00+163.16%
Max Forecast
$105.00+325.1%

Should I buy or sell RARE stock?

Based on 11 analysts offering ratings for Ultragenyx Pharmaceutical Inc.

Strong Buy
Strong Buy
8 analysts 72.73%
Buy
3 analysts 27.27%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although RARE's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates RARE as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their RARE stock forecasts and price targets.

RARE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-03
lockedlocked$00.00+00.00%2026-01-05
lockedlocked$00.00+00.00%2026-01-02
lockedlocked$00.00+00.00%2025-12-30
lockedlocked$00.00+00.00%2025-12-30
Wells Fargo
Top 34%
67
Strong BuyMaintains$45.00+82.19%2025-12-30
Jefferies
Bottom 4%
4
Strong BuyMaintains$63.00+155.06%2025-12-30
Barclays
Top 28%
73
Strong BuyMaintains$50.00+102.43%2025-11-24
TD Cowen
Top 27%
74
Strong BuyMaintains$75.00+203.64%2025-11-05
Truist Securities
Top 2%
99
Strong BuyMaintains$90.00+264.37%2025-11-05

1 of 2

Forecast return on equity

Is RARE forecast to generate an efficient return?

Company
24,047.89%
Industry
335.63%
Market
216.58%
RARE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RARE forecast to generate an efficient return on assets?

Company
43.61%
Industry
119.72%
RARE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RARE earnings per share forecast

What is RARE's earnings per share in the next 3 years based on estimates from 22 analysts?

Avg 1 year Forecast
-$3.96
Avg 2 year Forecast
-$1.39
Avg 3 year Forecast
$1.68

RARE revenue forecast

What is RARE's revenue in the next 3 years based on estimates from 22 analysts?

Avg 1 year Forecast
$802.7M+27.29%
Avg 2 year Forecast
$1.2B+86.81%
Avg 3 year Forecast
$1.6B+149.76%
RARE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RARE revenue growth forecast

How is RARE forecast to perform vs Biotechnology companies and vs the US market?

Company
35.51%
Industry
115.73%
Market
23.06%
RARE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RARE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RARE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RARE$24.70$65.00+163.16%Strong Buy
TLX$7.10$21.00+195.77%Strong Buy
DYN$16.80$38.22+127.51%Strong Buy
ADPT$15.77$20.00+26.82%Strong Buy
MLYS$29.77$47.33+59.00%Strong Buy
View Top Biotech Stocks

Ultragenyx Pharmaceutical Stock Forecast FAQ

Is Ultragenyx Pharmaceutical Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 11 Wall Street analysts covering (NASDAQ: RARE) stock is to Strong Buy RARE stock.

Out of 11 analysts, 8 (72.73%) are recommending RARE as a Strong Buy, 3 (27.27%) are recommending RARE as a Buy, 0 (0%) are recommending RARE as a Hold, 0 (0%) are recommending RARE as a Sell, and 0 (0%) are recommending RARE as a Strong Sell.

If you're new to stock investing, here's how to buy Ultragenyx Pharmaceutical stock.

What is RARE's earnings growth forecast for 2026-2028?

(NASDAQ: RARE) Ultragenyx Pharmaceutical's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.03%.

Ultragenyx Pharmaceutical's earnings in 2026 is -$579,829,000.On average, 22 Wall Street analysts forecast RARE's earnings for 2026 to be -$381,800,332, with the lowest RARE earnings forecast at -$609,834,714, and the highest RARE earnings forecast at -$117,712,282. On average, 17 Wall Street analysts forecast RARE's earnings for 2027 to be -$134,393,254, with the lowest RARE earnings forecast at -$364,955,348, and the highest RARE earnings forecast at $221,348,487.

In 2028, RARE is forecast to generate $161,976,191 in earnings, with the lowest earnings forecast at $82,256,775 and the highest earnings forecast at $271,487,879.

What is RARE's revenue growth forecast for 2026-2028?

(NASDAQ: RARE) Ultragenyx Pharmaceutical's forecast annual revenue growth rate of 35.51% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.06%.

Ultragenyx Pharmaceutical's revenue in 2026 is $630,598,000.On average, 22 Wall Street analysts forecast RARE's revenue for 2026 to be $77,439,650,309, with the lowest RARE revenue forecast at $63,224,645,293, and the highest RARE revenue forecast at $91,535,987,916. On average, 19 Wall Street analysts forecast RARE's revenue for 2027 to be $113,650,576,282, with the lowest RARE revenue forecast at $85,093,215,858, and the highest RARE revenue forecast at $167,581,537,353.

In 2028, RARE is forecast to generate $151,952,171,175 in revenue, with the lowest revenue forecast at $82,370,618,861 and the highest revenue forecast at $231,642,643,169.

What is RARE's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: RARE) forecast ROA is 43.61%, which is lower than the forecast US Biotechnology industry average of 119.72%.

What is RARE's Price Target?

According to 11 Wall Street analysts that have issued a 1 year RARE price target, the average RARE price target is $65.00, with the highest RARE stock price forecast at $105.00 and the lowest RARE stock price forecast at $45.00.

On average, Wall Street analysts predict that Ultragenyx Pharmaceutical's share price could reach $65.00 by Feb 3, 2027. The average Ultragenyx Pharmaceutical stock price prediction forecasts a potential upside of 163.16% from the current RARE share price of $24.70.

What is RARE's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: RARE) Ultragenyx Pharmaceutical's current Earnings Per Share (EPS) is -$5.93. On average, analysts forecast that RARE's EPS will be -$3.96 for 2026, with the lowest EPS forecast at -$6.32, and the highest EPS forecast at -$1.22. On average, analysts forecast that RARE's EPS will be -$1.39 for 2027, with the lowest EPS forecast at -$3.78, and the highest EPS forecast at $2.29. In 2028, RARE's EPS is forecast to hit $1.68 (min: $0.85, max: $2.81).

What is RARE's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: RARE) forecast ROE is 24,047.89%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.